Genetics and a dig at rivals for the holidays

Share this article:

23andMe's crisis is DNA Spectrum's gain. The rival genetic testing service released an announcement Tuesday, saying that while 23andMe has angered the FDA by promoting product claims it cannot support, the Phoenix, AZ, company “continues to be committed to the protection of consumers in genetic testing.”

DNA Spectrum's announcement notes the company has a “cutting-edge lineup of genetic ancestry services,” and that it is ready to provide “the best personal genetics holiday gifts to share with family and friends.”

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Genentech shift could prove costly for hospitals

Genentech will use specialty distributors rather than wholesalers, hospitals pharmacy directors have learned.

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies